Local physician involved in clinical trials of Erivedge™ (Vismodegib), the First Medicine for Adults with Advanced Basal Cell Carcinoma

Houston, TX – February 3, 2012 – Genentech announced that Erivedge ™ (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with basal cell carcinoma (BCC, a type of skin cancer.) Erivedge™ was approved on January 30, 2012.

Dr. Leonard H. Goldberg, a Houston Dermatological surgeon, has been a clinical investigator for Genentech since 2009. “Involvement in these clinical trials has given us the opportunity to gather much needed information about this medication” said Dr. Goldberg.  “This drug will be life changing for some people with Basal Cell Carcinoma.”   The capsule, used once daily, treats advanced BCC, which, if left untreated, may enlarge and result in large tumors, deformity or loss of function.

Erivedge ™ will be distributed through specialty pharmacies. For more information about Erivedge ™, physicians may contact Erivedge ™ Access Solutions (http://www.ErivedgeAccessSolutions.com or 1-888-249-4918).

Comments are closed.

Back to Top